Necrosis in a Biomarker-driven, Phase 2 Trial of Adjuvant Apatinib in Patients of Nasopharyngeal Carcinoma with Residual Epstein–Barr Virus DNA after Radiotherapy
Necrosis in a Biomarker-driven, Phase 2 Trial of Adjuvant Apatinib in Patients of Nasopharyngeal Carcinoma with Residual Epstein–Barr Virus DNA after Radiotherapy
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started